Pular para o conteúdo principal
Ranking Invest

VNDA - Vanda Pharmaceuticals Inc.

Segmento: HealthcareVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Análise Ranking Invest

Valor de Mercado
$ 241.25 Mi
IVR
-0.43Índice proprietário de comparação relativa: -0,43.
IVR2
-1.36Leitura proprietária complementar: -136%.
MLL
-1.36Leitura proprietária complementar: -136%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 220.19 Mi

Dívida Líquida

-$ 55.88 Mi

L4T

-$ 274.85 Mi

MM4T

-126.13%

Indicadores Básicos

ROE

-124.83%

Índices de Previsibilidade

Receita Líquida

D0.10

Lucro

D0.53

Margem

C0.53

Índices de Tendência

Receita Líquida

D-2.55

Lucro

G-11.07

Margem

G-10.92

Índices de Endividamento

DIV/PAT

-0.25

DIV/L4T

0.20

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.